Table 1.
Signal transducer and activator of transcription 3 (STAT3) inhibitors currently in clinical trials.
| Inhibitor | Indication | Study Phase | Status | NCT Identifier |
|---|---|---|---|---|
| AZD9150 IONIS-STAT3Rx (STAT3 antisense oligonucleotide) |
NSCLC, advanced solid tumors | I/II | Recruiting | NCT03421353 |
| Advanced pancreatic cancer, NSCLC, and CRC | II | Recruiting | NCT02983578 | |
| Advanced/metastatic hepatocellular cancer | I | Completed | NCT01839604 | |
| DLBCL | I | Recruiting | NCT02549651 | |
| Advanced solid tumors, metastatic HNSCC | I/II | Recruiting | NCT02499328 | |
| Advanced tumors, DLBCL, lymphoma | I/II | Completed | NCT01563302 | |
| OPB-31121 (STAT3 SH2 domain) |
Advanced cancer, solid tumors | I | Completed | NCT00955812 |
| Advanced solid tumors | I | Unknown | NCT00657176 | |
| Hepatocellular carcinoma | I/II | Completed | NCT01406574 | |
| OPB-51602 (STAT3 SH2 domain) |
Advanced tumors | I | Completed | NCT01423903 |
| Multiple myeloma, NHL, AML, ALL, and CML | I | Completed | NCT01344876 | |
| Advanced solid tumors | I | Completed | NCT01184807 | |
| OPB-111077 (STAT3 phosphorylation) |
Advanced tumors | I | Completed | NCT01711034 |
| Napabucasin DSP-0337 (STAT3 SH2 domain) |
Metastatic pancreatic adenocarcinoma | III | Recruiting | NCT02993731 |
| Metastatic CRC | II | Not yet recruiting | NCT03647839 | |
| Advanced solid tumors | I | Not yet recruiting | NCT03416816 | |
| STAT3 DECOY (STAT3 response element) |
HNSCC | Early I | Completed | NCT00696176 |
| TTI-101 (STAT3 SH2 domain) |
Advanced tumors | I | Recruiting | NCT03195699 |
ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CML, chronic myeloid leukemia; CRC, colorectal cancer; DLBCL, diffuse large B-cell lymphoma; HNSCC, head and neck squamous cell carcinoma; NHL, non-Hodgkin lymphoma; NSCLC, non-small-cell lung cancer; SH2, Src homology domain 2; STAT3, signal transducer and activator of transcription 3.